CLCS — what changed in the latest 10-Q
A section-by-section comparison of CLCS's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-14 vs the prior 10-Q · 2024-11-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +3 | −11 | ~16 | 13 |
| Controls & procedures | Text added/removed | 0 | 0 | ~3 | 0 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | No paragraph-level changes | 0 | 0 | 0 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3)
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-14
Research and development expense was $515,183 and $356,213 for the three months ended March 31, 2025 and 2024, respectively, an increase of $158,970, or 45%. This increase is primarily due to additional incurred expenses as a result of the execution of new amendments with MD Anderson.
During the three months ended March 31, 2025 and 2024, we recognized a gain on the change in fair value of derivative and warrant liabilities of $30,610 and $91,493, respectively, a decrease of $60,883, or 67%. The change in the fair value of our derivative and warrant liabilities during each period…
Net cash provided by financing activities for the three months ended March 31, 2025 and 2024 was approximately $527,000 and $152,000, respectively. The net cash provided by financing activities during the three months ended March 31, 2025 was attributable to $150,000 of proceeds from the future issu…
Text removed vs the prior filing · source: 10-Q · 2024-11-14
Research and development expense was $360,857 and $514,505 for the three months ended September 30, 2024 and 2023, respectively, a decrease of $153,648, or 30%. This decrease is primarily attributable to no patients being enrolled in the three months ended September 30, 2024 by MD Anderson.
During the three months ended September 30, 2024, we recognized a gain on the change in fair value of derivative liability of $98,550.
During the three months ended September 30, 2024, we recognized a gain on the extinguishment of a note payable of $17,893 via the issuance of warrants. The gain on extinguishment of note payable is attributable to the exchange of a promissory note in the principal amount of $30,000 for a five-year w…
Nine Months Ended September 30, 2024 Compared with the Nine Months Ended September, 2023
Research and development expense was $1,537,081 and $1,218,593 for the nine months ended September 30, 2024 and 2023, respectively, an increase of $318,488, or 26%. This increase is primarily attributable to a patient enrollment milestone being achieved during the 2024 period, compared to no patient…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice